Bhatt Padmanabh P.
Insider CIK 1539215 · SUPN Sr.VP of IP, CSO
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-10-30 | 2026-11-02 | 100,000 | — | $0 | 100,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-08-12 | 2026-08-14 | 2,500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-08-12 | 2026-08-14 | 2,500 | — | $0 | 19,795 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-08-12 | 2026-08-14 | 1,158 | $46.57 | $53.9K | 18,637 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-08-12 | 2026-08-14 | 2,500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-08-12 | 2026-08-14 | 1,158 | $46.57 | $53.9K | 18,637 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-08-12 | 2026-08-14 | 2,500 | — | $0 | 19,795 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-07-29 | 2026-07-31 | 2,500 | — | $0 | 2,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-07-29 | 2026-07-31 | 2,500 | — | $0 | 2,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-03-18 | 2026-03-18 | 7,250 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2026-03-18 | 2026-03-18 | 6,838 | $49.55 | $338.8K | 17,456 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-03-18 | 2026-03-18 | 7,250 | $39.40 | $285.6K | 24,294 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2026-03-18 | 2026-03-18 | 412 | $50.48 | $20.8K | 17,044 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-03-17 | 2026-03-18 | 15,000 | — | $0 | 5,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-03-17 | 2026-03-18 | 12,250 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-03-17 | 2026-03-18 | 22,750 | — | $0 | 7,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2026-03-17 | 2026-03-18 | 22,290 | $50.73 | $1.13M | 17,044 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2026-03-17 | 2026-03-18 | 27,710 | $49.95 | $1.38M | 39,334 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-03-17 | 2026-03-18 | 15,000 | $38.60 | $579.0K | 67,044 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-03-17 | 2026-03-18 | 12,250 | $36.75 | $450.2K | 52,044 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-03-17 | 2026-03-18 | 22,750 | $39.40 | $896.4K | 39,794 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-03-16 | 2026-03-18 | 5,000 | — | $0 | 15,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-03-16 | 2026-03-18 | 18,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-03-16 | 2026-03-18 | 4,250 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-03-16 | 2026-03-18 | 22,750 | — | $0 | 12,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2026-03-16 | 2026-03-18 | 15,886 | $50.49 | $802.1K | 17,044 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2026-03-16 | 2026-03-18 | 34,114 | $50.18 | $1.71M | 32,930 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-03-16 | 2026-03-18 | 5,000 | $27.94 | $139.7K | 67,044 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-03-16 | 2026-03-18 | 18,000 | $32.20 | $579.6K | 62,044 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-03-16 | 2026-03-18 | 4,250 | $29.61 | $125.8K | 44,044 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-03-16 | 2026-03-18 | 22,750 | $36.75 | $836.1K | 39,794 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-25 | 2026-02-26 | 1,250 | — | $0 | 1,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-25 | 2026-02-26 | 650 | $50.69 | $32.9K | 17,044 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-25 | 2026-02-26 | 1,250 | — | $0 | 17,694 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-24 | 2026-02-25 | 1,250 | — | $0 | 2,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-24 | 2026-02-25 | 750 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-24 | 2026-02-25 | 1,125 | — | $0 | 3,375 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-24 | 2026-02-25 | 750 | — | $0 | 16,194 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-24 | 2026-02-25 | 581 | $51.35 | $29.8K | 15,444 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-24 | 2026-02-25 | 646 | $50.86 | $32.9K | 16,444 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-24 | 2026-02-25 | 354 | $50.86 | $18.0K | 15,840 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-24 | 2026-02-25 | 1,250 | — | $0 | 17,090 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-24 | 2026-02-25 | 1,125 | — | $0 | 16,025 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-02-18 | 2026-02-20 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-02-18 | 2026-02-20 | 13,500 | — | $0 | 13,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-12-18 | 2025-12-19 | 1,500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-12-18 | 2025-12-19 | 1,500 | — | $0 | 15,218 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-12-18 | 2025-12-19 | 710 | $44.44 | $31.6K | 14,508 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-11-13 | 2025-11-17 | 1,500 | — | $0 | 1,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-08-25 | 2025-08-27 | 1,250 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-08-25 | 2025-08-27 | 581 | $41.46 | $24.1K | 13,718 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-08-25 | 2025-08-27 | 1,250 | — | $0 | 14,299 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-08-07 | 2025-08-08 | 1,250 | — | $0 | 1,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-05 | 2025-03-05 | 335 | $33.05 | $11.1K | 13,854 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-05 | 2025-03-05 | 575 | $33.05 | $19.0K | 13,279 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-05 | 2025-03-05 | 575 | $33.05 | $19.0K | 12,704 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2025-02-23 | 2025-02-24 | 1,250 | — | $0 | 2,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2025-02-23 | 2025-02-24 | 1,250 | — | $0 | 14,189 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2025-02-22 | 2025-02-24 | 1,250 | — | $0 | 3,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2025-02-22 | 2025-02-24 | 750 | — | $0 | 750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2025-02-22 | 2025-02-24 | 1,250 | — | $0 | 12,939 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2025-02-22 | 2025-02-24 | 750 | — | $0 | 11,689 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-02-21 | 2025-02-24 | 1,650 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-02-21 | 2025-02-24 | 1,650 | — | $0 | 11,799 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-02-21 | 2025-02-24 | 860 | $39.15 | $33.7K | 10,939 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-19 | 2025-02-21 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-19 | 2025-02-21 | 4,500 | — | $0 | 4,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-02-04 | 2025-02-05 | 9,477 | — | $0 | 4,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-02-04 | 2025-02-05 | 9,477 | $39.70 | $376.2K | 10,149 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-02-04 | 2025-02-05 | 9,477 | $29.61 | $280.6K | 19,626 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-01-28 | 2025-01-29 | 700 | — | $0 | 9,477 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-01-28 | 2025-01-29 | 1,650 | — | $0 | 1,650 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-01-28 | 2025-02-05 | 700 | — | $0 | 13,727 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-01-28 | 2025-01-29 | 700 | $29.61 | $20.7K | 10,849 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-01-28 | 2025-01-29 | 700 | $39.62 | $27.7K | 10,149 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-01-27 | 2025-01-29 | 2,573 | — | $0 | 10,177 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-01-27 | 2025-01-29 | 2,573 | $29.61 | $76.2K | 12,722 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-01-27 | 2025-01-29 | 2,573 | $39.62 | $101.9K | 10,149 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-12-03 | 2024-12-04 | 12,745 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-12-03 | 2024-12-04 | 8,750 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2024-12-03 | 2024-12-04 | 12,745 | $36.68 | $467.5K | 9,679 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-12-03 | 2024-12-04 | 8,750 | $23.99 | $209.9K | 18,429 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-12-03 | 2024-12-04 | 12,745 | $25.30 | $322.4K | 22,424 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2024-12-03 | 2024-12-04 | 8,750 | $36.68 | $320.9K | 9,679 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-08-20 | 2024-08-20 | 1,250 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-08-20 | 2024-08-20 | 1,250 | — | $0 | 10,251 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-08-20 | 2024-08-20 | 572 | $29.57 | $16.9K | 9,679 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-08-01 | 2024-08-14 | 1,250 | — | $0 | 1,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-03-21 | 2024-03-25 | 14,491 | — | $0 | 12,745 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2024-03-21 | 2024-03-25 | 14,491 | $35.31 | $511.7K | 8,570 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-03-21 | 2024-03-25 | 14,491 | $25.30 | $366.6K | 23,061 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-03-20 | 2024-03-22 | 400 | — | $0 | 27,236 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-03-20 | 2024-03-22 | 400 | $25.30 | $10.1K | 8,970 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2024-03-20 | 2024-03-22 | 400 | $35.31 | $14.1K | 8,570 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-03-19 | 2024-03-21 | 12,364 | — | $0 | 27,636 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-03-19 | 2024-03-21 | 12,364 | $25.30 | $312.8K | 20,934 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2024-03-19 | 2024-03-21 | 12,364 | $35.31 | $436.6K | 8,570 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-03-13 | 2024-03-15 | 36,116 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-03-13 | 2024-03-15 | 26,250 | — | $0 | 8,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2024-03-13 | 2024-03-15 | 26,250 | $34.10 | $895.1K | 8,570 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-03-13 | 2024-03-15 | 36,116 | $12.98 | $468.8K | 44,686 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2024-03-13 | 2024-03-15 | 36,116 | $33.48 | $1.21M | 8,570 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-03-13 | 2024-03-15 | 26,250 | $23.99 | $629.7K | 34,820 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-03-12 | 2024-03-14 | 3,884 | — | $0 | 36,116 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2024-03-12 | 2024-03-14 | 3,884 | $32.99 | $128.1K | 8,570 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-03-12 | 2024-03-14 | 3,884 | $12.98 | $50.4K | 12,454 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-02-26 | 2024-02-28 | 5,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-02-26 | 2024-02-28 | 5,000 | $9.13 | $45.7K | 13,570 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2024-02-26 | 2024-02-28 | 5,000 | $30.21 | $151.1K | 8,570 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2024-02-23 | 2024-02-27 | 1,250 | — | $0 | 3,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2024-02-23 | 2024-02-27 | 1,250 | — | $0 | 9,208 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-02-23 | 2024-02-27 | 638 | $29.06 | $18.5K | 8,570 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2024-02-22 | 2024-02-26 | 750 | — | $0 | 1,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-02-22 | 2024-02-26 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-02-22 | 2024-02-26 | 5,000 | — | $0 | 5,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2024-02-22 | 2024-02-26 | 750 | — | $0 | 8,330 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-02-22 | 2024-02-26 | 372 | $27.94 | $10.4K | 7,958 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-09-07 | 2023-09-07 | 2,500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-09-07 | 2023-09-07 | 2,500 | — | $0 | 8,347 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2023-09-07 | 2023-09-07 | 1,182 | $32.10 | $37.9K | 7,165 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-08-23 | 2023-08-25 | 2,500 | — | $0 | 2,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-05-11 | 2023-05-12 | 750 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-05-11 | 2023-05-12 | 750 | — | $0 | 5,497 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-05-04 | 2023-05-08 | 750 | — | $0 | 750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2023-04-11 | 2023-04-12 | 1,500 | — | $0 | 4,747 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-23 | 2023-02-27 | 5,000 | — | $0 | 5,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-23 | 2023-02-27 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2023-02-22 | 2023-02-24 | 750 | — | $0 | 2,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2023-02-22 | 2023-02-24 | 750 | — | $0 | 3,247 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-01-17 | 2023-01-19 | 4,826 | — | $0 | 5,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2023-01-17 | 2023-01-19 | 4,826 | $39.92 | $192.7K | 1,644 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-01-17 | 2023-01-19 | 4,826 | $9.13 | $44.1K | 6,470 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-01-06 | 2023-01-09 | 174 | — | $0 | 9,826 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-01-06 | 2023-01-09 | 174 | $9.13 | $1.6K | 1,818 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2023-01-06 | 2023-01-09 | 174 | $39.90 | $6.9K | 1,644 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-12-01 | 2022-12-02 | 5,000 | — | $0 | 10,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-12-01 | 2022-12-02 | 5,000 | $9.13 | $45.7K | 6,644 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-12-01 | 2022-12-02 | 5,000 | $37.48 | $187.4K | 1,644 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-11-11 | 2022-11-15 | 6,800 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-11-11 | 2022-11-15 | 6,800 | $9.24 | $62.8K | 8,444 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-11-11 | 2022-11-15 | 6,800 | $34.95 | $237.7K | 1,644 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-11-09 | 2022-11-14 | 700 | — | $0 | 6,800 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-11-09 | 2022-11-14 | 700 | $34.97 | $24.5K | 1,644 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-11-09 | 2022-11-14 | 700 | $9.24 | $6.5K | 2,344 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2022-07-15 | 2022-08-05 | 750 | — | $0 | 1,644 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-24 | 18,000 | — | $0 | 18,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-24 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-25 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-25 | 18,000 | — | $0 | 18,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2021-02-19 | 2021-02-23 | 17,000 | — | $0 | 17,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2020-02-21 | 2020-02-25 | 35,000 | — | $0 | 35,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2019-02-22 | 2019-02-26 | 35,000 | — | $0 | 35,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2018-06-29 | 2018-06-29 | 4,393 | $59.90 | $263.1K | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2018-06-28 | 2018-06-29 | 295 | — | $0 | 15,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2018-06-28 | 2018-06-29 | 295 | $9.13 | $2.7K | 7,795 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2018-06-28 | 2018-06-29 | 3,402 | $59.94 | $203.9K | 4,393 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2018-06-21 | 2018-06-22 | 7,205 | — | $0 | 15,295 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2018-06-21 | 2018-06-22 | 7,205 | $9.13 | $65.8K | 14,705 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2018-06-21 | 2018-06-22 | 7,205 | $60.00 | $432.3K | 7,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2018-05-15 | 2018-05-16 | 368 | — | $0 | 7,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2018-05-15 | 2018-05-16 | 7,500 | — | $0 | 22,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2018-05-15 | 2018-05-16 | 7,500 | $57.93 | $434.5K | 7,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2018-05-15 | 2018-05-16 | 368 | $57.93 | $21.3K | 7,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2018-05-15 | 2018-05-16 | 7,500 | $9.13 | $68.5K | 15,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2018-05-15 | 2018-05-16 | 368 | $9.24 | $3.4K | 7,868 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2018-05-11 | 2018-05-14 | 20,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2018-05-11 | 2018-05-14 | 11,250 | — | $0 | 18,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2018-05-11 | 2018-05-14 | 10,882 | — | $0 | 7,868 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2018-05-11 | 2018-05-14 | 20,000 | $52.03 | $1.04M | 12,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2018-05-11 | 2018-05-14 | 10,882 | $9.24 | $100.5K | 18,382 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2018-05-11 | 2018-05-14 | 16,250 | $55.23 | $897.5K | 7,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2018-05-11 | 2018-05-14 | 11,250 | $9.24 | $104.0K | 23,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2018-05-11 | 2018-05-14 | 10,882 | $57.90 | $630.1K | 7,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2018-05-11 | 2018-05-14 | 20,000 | $7.90 | $158.0K | 32,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2018-05-10 | 2018-05-14 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2018-05-10 | 2018-05-14 | 20,000 | $49.88 | $997.6K | 12,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2018-05-10 | 2018-05-14 | 20,000 | $7.90 | $158.0K | 32,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2018-02-14 | 2018-02-16 | 30,000 | — | $0 | 30,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2018-01-22 | 2018-01-22 | 20,000 | — | $0 | 40,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2018-01-22 | 2018-01-22 | 20,000 | $48.04 | $960.8K | 12,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2018-01-22 | 2018-01-22 | 20,000 | $7.90 | $158.0K | 32,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2018-01-17 | 2018-01-17 | 20,000 | — | $0 | 60,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2018-01-17 | 2018-01-17 | 20,000 | $44.98 | $899.6K | 12,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2018-01-17 | 2018-01-17 | 20,000 | $7.90 | $158.0K | 32,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2017-09-08 | 2017-09-11 | 5,000 | $49.86 | $249.3K | 12,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2017-08-16 | 2017-08-16 | 3,709 | $45.23 | $167.8K | 17,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2017-07-12 | 2017-07-14 | 3,735 | $44.90 | $167.7K | 21,209 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2017-06-23 | 2017-06-27 | 2,556 | $44.90 | $114.8K | 24,944 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2017-06-02 | 2017-06-05 | 10,000 | $39.86 | $398.6K | 27,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2017-05-26 | 2017-05-30 | 2,500 | $35.90 | $89.8K | 37,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2017-05-25 | 2017-05-25 | 3,887 | $34.90 | $135.7K | 40,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2017-05-24 | 2017-05-25 | 1,613 | $34.90 | $56.3K | 43,887 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2017-04-24 | 2017-04-24 | 11,806 | $32.59 | $384.8K | 45,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2017-02-24 | 2017-02-27 | 40,000 | — | $0 | 40,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2016-04-11 | 2016-04-12 | 30,762 | $16.49 | $507.3K | 57,306 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2016-03-01 | 2016-03-03 | 40,000 | — | $0 | 40,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2015-12-09 | 2015-12-10 | 4,685 | $14.90 | $69.8K | 88,068 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2015-12-08 | 2015-12-10 | 9,553 | $14.90 | $142.3K | 92,753 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2015-11-04 | 2015-11-06 | 5,000 | $19.90 | $99.5K | 102,306 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2015-03-03 | 2015-03-05 | 30,000 | — | $0 | 30,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2015-01-15 | 2015-01-16 | 37,500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2015-01-15 | 2015-01-16 | 37,500 | $2.56 | $96.0K | 107,306 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2015-01-05 | 2015-01-08 | 2,500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2015-01-05 | 2015-01-08 | 3,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2015-01-05 | 2015-01-08 | 12,500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2015-01-05 | 2015-01-08 | 3,000 | $0.40 | $1.2K | 67,306 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2015-01-05 | 2015-01-08 | 2,500 | $3.36 | $8.4K | 69,806 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2015-01-05 | 2015-01-08 | 12,500 | $0.40 | $5.0K | 64,306 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2014-01-21 | 2014-01-23 | 30,000 | — | $0 | 30,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | S Sale | 2013-08-19 | 2013-08-21 | 2,285 | $8.21 | $18.8K | 51,806 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2013-02-08 | 2013-02-12 | 25,000 | — | $0 | 12,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2013-02-08 | 2013-02-12 | 25,000 | $0.40 | $10.0K | 51,806 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2013-02-05 | 2013-02-07 | 80,000 | — | $0 | 80,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2012-06-18 | 2012-06-20 | 25,000 | — | $0 | 37,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2012-06-18 | 2012-06-20 | 25,000 | $0.40 | $10.0K | 25,000 | SEC↗ |